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Résumé en
anglais
The present final consensus statement of the French Society of Endocrinology lays out
the assessments that are to be systematically performed before and during anticancer
treatment by immunotherapy, tyrosine kinase inhibitors or mTOR inhibitors, even
without onset of any endocrinopathy. It also discusses the CTCAE adverse event
grading system in oncology and the difficulty of implementing it for endocrine side-
effects of these anticancer treatments. Notably, this is why certain treatment steps
applied in other side-effects (e.g., high-dose corticosteroids, contraindications to
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